Skip to content
value.today

Expansion Therapeutics, Inc.

🇺🇸 Del Mar, California, USAPharmaceuticalsFounded 2016
Total raised
$73 M
2 rounds on record
Latest round
$48 M
Sep 2021
First round on record
Dec 2017
Today
Private
No later event on record

Funding rounds

2 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Expansion Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Sep 2021$48 MNo. 2$10 to $50 million

Expansion Therapeutics, Inc.: Raise no. 2, Sep 2021

Investors in this round

12 investors had bought by the notice of Oct 12, 2021: 12 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$48 M of $80 M offered; $32 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Renato Skerlj, Ph.D. · Executive Officer, Director
  • Andy Phillips, Ph.D. · Director
  • Beth Seidenberg, M.D. · Director
  • Laura Tadvalkar, Ph.D. · Director
  • Scott Rocklage, Ph.D. · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Renato Skerlj, Ph.D., Chief Executive Officer. Source: SEC Form D, newest notice filed Oct 12, 2021. Read the notice at the SEC.

equitySEC
Dec 2017$25 MNo. 1$10 to $50 million

Expansion Therapeutics, Inc.: Raise no. 1, Dec 2017

Investors in this round

8 investors had bought by the notice of Jan 3, 2018: 8 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$25 M of $55 M offered; $30 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Kevin Forrest, Ph.D. · Executive Officer, Director
  • Beth Seidenberg, M.D. · Director
  • Campbell Murray, M.B.B.S., M.B.A. · Director
  • Jason Hafler, Ph.D. · Director
  • Matthew Disney, Ph.D. · Director
  • Scott Rocklage, Ph.D. · Director
  • Yujiro Hata, M.B.A. · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Total Offering Amount and Total Amount Sold includes amounts paid pursuant to conversion of indebtedness.”

Signed by Kevin Forrest, Ph.D., President and Chief Executive Officer. Source: SEC Form D, newest notice filed Jan 3, 2018. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Expansion Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Oct 2021).

    SEC Form D · Oct 2021

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Oct 2021

That is all the official record says: Expansion Therapeutics, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Expansion Therapeutics, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 12 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Expansion Therapeutics, Inc.
NameRoleNamed in
Renato Skerlj, Ph.D.Executive officerOct 2021
Kevin Forrest, Ph.D.Executive officerJan 2018
Andy Phillips, Ph.D.DirectorOct 2021
Beth Seidenberg, M.D.DirectorOct 2021
Laura Tadvalkar, Ph.D.DirectorOct 2021
Renato Skerlj, Ph.D.DirectorOct 2021
Scott Rocklage, Ph.D.DirectorOct 2021
Campbell Murray, M.B.B.S., M.B.A.DirectorJan 2018
Jason Hafler, Ph.D.DirectorJan 2018
Kevin Forrest, Ph.D.DirectorJan 2018
Matthew Disney, Ph.D.DirectorJan 2018
Yujiro Hata, M.B.A.DirectorJan 2018